<?xml version="1.0" encoding="UTF-8"?>
<p id="Par48">The manufacturing process for cell-based IIV is similar to egg-based IIVs, but has several advantages over the latter (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>). Viral production in a cell culture bioreactor is more flexible, more scalable and unaffected by egg shortages. Additionally, recent comparisons have shown that cell-based vaccines provided a moderately higher VE for elderly individuals (≧65 years old) than egg-based vaccines, possibly due to less egg-adapted mutations [
 <xref ref-type="bibr" rid="CR38">38</xref>].
</p>
